Coprimary endpoints—OS & PFS
Coprimary endpoints—OS & PFS
Primary OS analysis
1L=first line; ADA=antidrug antibody; CI=confidence interval; HR=hazard ratio; mHCC=metastatic hepatocellular carcinoma; NE=not estimable; OS=overall survival.
Updated OS analysis
Landmark analyses were not powered to demonstrate statistically significant differences and no conclusions can be drawn from these analyses. The OS rates at 6, 12, and 18 months were estimated with the use of Kaplan-Meier methodology for each treatment arm.
Discover exploratory OS results based on high-risk characteristics historically excluded from 1L HCC trials8
HSCT=hematopoietic stem cell transplantation; ITT=intent to treat.
Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.
Please see below and the TECENTRIQ Prescribing Information for additional Important Safety Information.
Progression-free survival
IRF=independent review facility; PFS=progression-free survival; RECIST=Response Evaluation Criteria In Solid Tumors.
TECENTRIQ Prescribing Information. Genentech, Inc.
TECENTRIQ Prescribing Information. Genentech, Inc.
Data on file. Genentech, Inc.
Data on file. Genentech, Inc.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hepatocellular Carcinoma V.4.2024. National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 10, 2025. To view the most recent and complete version of the guideline, go online to www.NCCN.org.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hepatocellular Carcinoma V.4.2024. National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed January 10, 2025. To view the most recent and complete version of the guideline, go online to www.NCCN.org.
Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers. 2019;11:841.
Li D, Sedano S, Allen R, Gong J, Cho M, Sharma S. Current treatment landscape for advanced hepatocellular carcinoma: patient outcomes and the impact on quality of life. Cancers. 2019;11:841.
Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.
Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.
Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
Finn RS, Qin S, Ikeda M, et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-873.
Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-873.
Finn RS, Galle PR, Ducreux M, et al. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150. Liver Cancer. 2024;13:655-668. doi:10.1159/000539897
Finn RS, Galle PR, Ducreux M, et al. Efficacy and safety of atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma with main trunk and/or contralateral portal vein invasion in IMbrave150. Liver Cancer. 2024;13:655-668. doi:10.1159/000539897
Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471.
Quirk M, Kim YH, Saab S, Lee EW. Management of hepatocellular carcinoma with portal vein thrombosis. World J Gastroenterol. 2015;21:3462-3471.
Khan AR, Wei X, Xu X. Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides. J Hepatocell Carcinoma. 2021;8:1089-1115.
Khan AR, Wei X, Xu X. Portal vein tumor thrombosis and hepatocellular carcinoma - the changing tides. J Hepatocell Carcinoma. 2021;8:1089-1115.
Merle P, Ducreux M, Finn RS, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab vs sorafenib by baseline varices status in patients with hepatocellular carcinoma. Presented at: The 11th Asia-Pacific Primary Liver Cancer Expert Meeting: August 13-15, 2021; virtual conference.
Merle P, Ducreux M, Finn RS, et al. IMbrave150: efficacy and safety of atezolizumab plus bevacizumab vs sorafenib by baseline varices status in patients with hepatocellular carcinoma. Presented at: The 11th Asia-Pacific Primary Liver Cancer Expert Meeting: August 13-15, 2021; virtual conference.
Data on file. Clinical Study Report Y040245. Genentech, Inc.
Data on file. Clinical Study Report Y040245. Genentech, Inc.
Singal A, Llovet J, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-1965.
Singal A, Llovet J, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-1965.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65:310-335.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65:310-335.
Data on file. Study Protocol Y040245. Genentech, Inc.
Data on file. Study Protocol Y040245. Genentech, Inc.
Galle PR, Finn RS, Shukurui Q, et al; Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991-1001.
Galle PR, Finn RS, Shukurui Q, et al; Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:991-1001.
Avastin (bevacizumab) Prescribing Information. Genentech, Inc.
Avastin (bevacizumab) Prescribing Information. Genentech, Inc.
Breder VV, Vogel A, Merle P, et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab + bevacizumab versus sorafenib in a global phase III study. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021; virtual conference.
Breder VV, Vogel A, Merle P, et al. IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab + bevacizumab versus sorafenib in a global phase III study. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021; virtual conference.
Data on file. Roche.
Data on file. Roche.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.